Verve Therapeutics Q2 2024 GAAP EPS $(0.59) Beats $(0.71) Estimate, Sales $6.692M Beat $2.030M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $575.9M; Cash Runway Into Late 2026
Portfolio Pulse from Benzinga Newsdesk
Verve Therapeutics reported a Q2 2024 GAAP EPS of $(0.59), beating the estimate of $(0.71). Sales were $6.692M, surpassing the $2.030M estimate. The company has $575.9M in cash, cash equivalents, and marketable securities, providing a cash runway into late 2026.
August 08, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verve Therapeutics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.59) and sales of $6.692M, both beating estimates. The company also has a strong cash position of $575.9M, ensuring a cash runway into late 2026.
The better-than-expected earnings and revenue figures, along with a strong cash position, are likely to positively impact Verve Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100